Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
30.00
-0.61 (-1.99%)
At close: May 14, 2025, 4:00 PM
30.60
+0.60 (2.00%)
After-hours: May 14, 2025, 5:22 PM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
According to 17 professional analysts, the 12-month price target for Cytokinetics stock ranges from a low of $41 to a high of $120. The average analyst price target of $75.65 forecasts a 152.17% increase in the stock price over the next year.
Price Target: $75.65 (+152.17%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 6 |
| Buy | 8 | 8 | 9 | 9 | 10 | 9 |
| Hold | 4 | 3 | 2 | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 17 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +140.00% | May 14, 2025 |
| Barclays | Barclays | Buy Maintains $55 → $53 | Buy | Maintains | $55 → $53 | +76.67% | May 8, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $82 → $80 | Buy | Maintains | $82 → $80 | +166.67% | May 7, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $86 → $80 | Strong Buy | Maintains | $86 → $80 | +166.67% | May 7, 2025 |
| UBS | UBS | Hold Maintains $47 → $41 | Hold | Maintains | $47 → $41 | +36.67% | May 2, 2025 |
Financial Forecast
Revenue This Year
27.79M
from 18.47M
Increased by 50.43%
Revenue Next Year
191.55M
from 27.79M
Increased by 589.25%
EPS This Year
-5.84
from -5.26
EPS Next Year
-4.78
from -5.84
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 67.3M | 415.8M | 827.5M | ||
| Avg | 27.8M | 191.6M | 461.5M | ||
| Low | 5.9M | 53.0M | 273.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 264.3% | 1,396.2% | 332.0% | ||
| Avg | 50.4% | 589.3% | 140.9% | ||
| Low | -68.2% | 90.8% | 42.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.15 | -3.38 | -0.72 | ||
| Avg | -5.84 | -4.78 | -2.50 | ||
| Low | -6.56 | -6.37 | -4.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.